-
08:13:38 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

Trending News

Stock Market News LIVE

The stock market news feed is automatically updated to show the latest 50 news.
The news is in real time for GOLD users while a 15 second delay is applied for FREE users.

Become a Gold member to unlock the feed filters, voice notification and see the news without delay.

Stock Market News Today - Join our Discord

Do NOT follow this link!
09/23/21 7:48 AM
OTC : APLIF
clinical trialcovid-19
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced it has completed enrollment in its global Phase 3 PRESECO trial evaluating oral Avigan ®/ Reeqonus™ as a potential COVID-19 treatment. With today’ s announcement, the double-blind, placebo-controlled, randomized, global,...
RHEA-AI
neutral
09/22/21 9:44 PM
NYSE, Nasdaq : PFE, BNTX
covid-19
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose...
RHEA-AI
neutral
09/22/21 4:01 PM
Nasdaq : ARCT
covid-19
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Arcturus’ President& CEO, Joseph Payne, met with the President of Vietnam, Nguyen Xuan Phuc, and the CEO of...
RHEA-AI
neutral
09/22/21 9:01 AM
Nasdaq : GILD
covid-19
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Gilead Sciences, Inc. today announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury ® for intravenous use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. Enrollment for this trial was stopped prior to...
RHEA-AI
neutral
09/22/21 8:17 AM
Nasdaq : BIOC
covid-19
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, has implemented its COVID-19 testing services at more than 30 community college campuses across California, streamlining the testing and tracking process for administrators, and allowing students and staff to easily schedule and complete COVID-19 testing.
RHEA-AI
neutral
09/22/21 8:00 AM
OTC : CYDY
clinical trialcovid-19
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Brazil’ s regulatory authority, ANVISA, has approved the start of an additional Phase 3 CD16 clinical trial of leronlimab. The Academic Research Organization Albert Einstein Israelite...
RHEA-AI
neutral
09/22/21 7:00 AM
Nasdaq : BCYP, BCYPU
covid-19
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that the U.S. Department of Defense has awarded the company an additional $60.5 million in expanded scope for its...
RHEA-AI
positive
09/22/21 6:02 AM
Nasdaq : BNTX
covid-19
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
Expanded agreement brings the total number of COVID-19 vaccine doses to be supplied to the U.S. government for donation to one billion Effort contributes to companies’ pledge to deliver two billion COVID-19 vaccine doses to low- and middle-income countries by the end of 2022 NEW YORK and MAINZ,
RHEA-AI
neutral
09/21/21 1:55 PM
Nasdaq : ABCL
covid-19
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
AbCellera today announced the European Commission and Eli Lilly and Company have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of...
RHEA-AI
neutral
09/21/21 12:31 PM
NYSE : C
covid-19
Citi Private Bank Finds Cautious Optimism Among Investors for 2022 with Covid-19, Inflation and Peak Market Valuations Top of Mind
Citi Private Bank’ s Private Capital Group today released the results of its 2021 Family Office Survey, compiling the unique perspectives and insights of many of the world’ s sophisticated family offices and ultra-high net worth investors in a challenging climate. While over three-fourths of all respondents seek returns of 5% or more over the next 12 months,...
RHEA-AI
neutral
09/20/21 7:44 AM
OTC : APLIF
clinical trialcovid-19
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced it entered into an agreement with FUJIFILM Toyama Chemical Co., Ltd., that will provide funding support for its Phase 3 PRESECO clinical trial. As part of the agreement, FFTC will receive direct access to PRESECO data in support of local...
RHEA-AI
neutral
09/20/21 6:45 AM
NYSE, Nasdaq : PFE, BNTX
covid-19
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Results are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of age In participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses Companies plan to submit these data to the FDA, EMA and other regulatory agencies around the world as soon as possible Results in children...
RHEA-AI
neutral
09/17/21 8:00 AM
OTC : CYDY
covid-19
Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit
A group of long-time stockholders of CytoDyn Inc. that has nominated five highly experienced director candidates to serve on the Company’ s Board of Directors today announced that Bruce Patterson, M.D., one of the candidates, attended and presented at the International COVID Summit, held in Rome, Italy from September 12-14, 2021. Dr. Patterson was one of three...
RHEA-AI
positive
09/17/21 7:17 AM
OTC : APLIF
covid-19
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced it has completed patient enrollment in the viral shedding sub-study portion of its Phase 3 PRESECO trial evaluating Avigan ®/ Reeqonus™ as a potential oral antiviral COVID-19 treatment in the United States. The viral shedding...
RHEA-AI
neutral
09/16/21 4:15 PM
Nasdaq : ABCL
covid-19
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
AbCellera today announced the U.S. Food and Drug Administration has expanded the Emergency Use Authorization for bamlanivimab 700 mg administered with etesevimab 1400 mg to include post-exposure prophylaxis to prevent SARS-CoV-2 infection or symptomatic COVID-19. Eli Lilly and Company’ s study was conducted in partnership with the National Institute...
RHEA-AI
neutral
09/16/21 3:16 PM
OTC : DFCO
covid-19
Dalrada Corporation’s Pala Diagnostics Free COVID-19 Point-of-care Tests Proved Compliance for Nearly 3,000 Outdoor Festival Attendees
Dalrada Corporation is excited to share information on the Company’ s community outreach efforts that support free, on-site COVID-19 point-of-care tests at in-person events. Pala Diagnostics, LLC, a joint venture between Dalrada Health and Vivera Pharmaceuticals, Inc., is a fully operational national laboratory that processes point-of-care, EUA approved,...
RHEA-AI
neutral